Bendroflumethiazide: Difference between revisions

	WikiDoc Resources for Bendroflumethiazide
Articles
Most recent articles on Bendroflumethiazide Most cited articles on Bendroflumethiazide Review articles on Bendroflumethiazide Articles on Bendroflumethiazide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bendroflumethiazide Images of Bendroflumethiazide Photos of Bendroflumethiazide Podcasts & MP3s on Bendroflumethiazide Videos on Bendroflumethiazide
Evidence Based Medicine
Cochrane Collaboration on Bendroflumethiazide Bandolier on Bendroflumethiazide TRIP on Bendroflumethiazide
Clinical Trials
Ongoing Trials on Bendroflumethiazide at Clinical Trials.gov Trial results on Bendroflumethiazide Clinical Trials on Bendroflumethiazide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bendroflumethiazide NICE Guidance on Bendroflumethiazide NHS PRODIGY Guidance FDA on Bendroflumethiazide CDC on Bendroflumethiazide
Books
Books on Bendroflumethiazide
News
Bendroflumethiazide in the news Be alerted to news on Bendroflumethiazide News trends on Bendroflumethiazide
Commentary
Blogs on Bendroflumethiazide
Definitions
Definitions of Bendroflumethiazide
Patient Resources / Community
Patient resources on Bendroflumethiazide Discussion groups on Bendroflumethiazide Patient Handouts on Bendroflumethiazide Directions to Hospitals Treating Bendroflumethiazide Risk calculators and risk factors for Bendroflumethiazide
Healthcare Provider Resources
Symptoms of Bendroflumethiazide Causes & Risk Factors for Bendroflumethiazide Diagnostic studies for Bendroflumethiazide Treatment of Bendroflumethiazide
Continuing Medical Education (CME)
CME Programs on Bendroflumethiazide
International
Bendroflumethiazide en Espanol Bendroflumethiazide en Francais
Business
Bendroflumethiazide in the Marketplace Patents on Bendroflumethiazide
Experimental / Informatics
List of terms related to Bendroflumethiazide

Bendroflumethiazide
Clinical data
Pregnancy; category	Risk neonatal thrombocytopenia in 3rd trimester;
Routes of; administration	oral
ATC code	C03AA01 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only) ;
Pharmacokinetic data
Bioavailability	100%
Protein binding	96%
Metabolism	extensive
Elimination half-life	3-4 hours
Identifiers
	IUPAC name 3-benzyl-5,5-dioxo-9- (trifluoromethyl)-5λ6- thia-2,4-diazabicyclo[4.4.0]deca-7, 9,11-triene-8-sulfonamide;
CAS Number	73-48-3;
PubChem CID	2315;
DrugBank	APRD00666;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C15H14F3N3O4S2
Molar mass	421.417 g/mol

VisualWikitext

Revision as of 15:44, 27 July 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bendroflumethiazide (INN), formerly bendrofluazide (BAN), is a thiazide diuretic used to treat hypertension.

Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal convoluted tubule (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).

Adverse Reactions

Common Adverse Effects

postural hypotension
Hyponatraemia, hypokalaemia, hypercalcaemia
Gout
Impaired glucose tolerance
Impotence

Rare Adverse Effects

Pill Images

{{#ask: Page Name::Bendroflumethiazide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }} {{#subobject:

 |Page Name=Bendroflumethiazide
 |Pill Name=CORZIDE_NDC_607930283.jpg
 |Drug Name=CORZIDE
 |Pill Ingred=NADOLOL[NADOLOL];BENDROFLUMETHIAZIDE[BENDROFLUMETHIAZIDE]|+sep=;
 |Pill Imprint=KPI;283;Corzide;40;5
 |Pill Dosage=5 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=9
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=King Pharmaceuticals, Inc.
 |NDC=607930283

}}

{{#subobject:

 |Page Name=Bendroflumethiazide
 |Pill Name=CORZIDE_NDC_607930284.jpg
 |Drug Name=CORZIDE
 |Pill Ingred=NADOLOL[NADOLOL];BENDROFLUMETHIAZIDE[BENDROFLUMETHIAZIDE]|+sep=;
 |Pill Imprint=KPI;284;Corzide;80;5
 |Pill Dosage=5 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=10
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=King Pharmaceuticals, Inc.
 |NDC=607930284

}}

References

↑ BNF 45 March 2003
↑ Ed. Sean C. Sweetman (ed.). Martindale: The complete drug reference (33 ed.). Pharmaceutical Press.

[1] BNF 45 March 2003

[2] Ed. Sean C. Sweetman (ed.). Martindale: The complete drug reference (33 ed.). Pharmaceutical Press.

[1]

[2]

@@ Line 1: / Line 1: @@
-__NOTOC__
 {{drugbox
 | IUPAC_name = 3-benzyl-5,5-dioxo-9- (trifluoromethyl)-5λ<sup>6</sup>- thia-2,4-diazabicyclo[4.4.0]deca-7, 9,11-triene-8-sulfonamide
@@ Line 26: / Line 25: @@
 | routes_of_administration = oral
 }}
+__NOTOC__
+{{SI}}
 {{CMG}}
+==Overview==
+'''Bendroflumethiazide''' ([[International Nonproprietary Name|INN]]), formerly '''bendrofluazide''' ([[British Approved Name|BAN]]), is a [[thiazide]] [[diuretic]] used to treat [[hypertension]].
+Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the [[distal convoluted tubule]] (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild [[heart failure]] although [[loop diuretic]]s are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to [[vasodilation]]).
-'''Bendroflumethiazide''' [[International Nonproprietary Name|INN]] (formerly [[British Approved Name|BAN]] '''bendrofluazide'''), is a [[thiazide]] [[diuretic]], used to treat [[hypertension]].
+==Adverse Reactions==
+===Common Adverse Effects===
+* [[Orthostatic hypotension|postural hypotension]]
+* [[Hyponatraemia]], [[hypokalaemia]], [[hypercalcaemia]]
+* [[Gout]]
+* Impaired glucose tolerance
+* [[Impotence]]
+===Rare Adverse Effects===
+* [[Thrombocytopenia]]
+* [[Agranulocytosis]]
+* [[Photosensitivity]] [[rash]]
+* [[Pancreatitis]]
 ==Pill Images==
@@ Line 37: / Line 56: @@
 {{PillImage|fileName=CORZIDE_NDC_607930284.jpg|drugName=CORZIDE|NDC=607930284|drugAuthor=King Pharmaceuticals, Inc.|ingredients=NADOLOL[NADOLOL];BENDROFLUMETHIAZIDE[BENDROFLUMETHIAZIDE]|pillImprint=KPI;284;Corzide;80;5|dosageValue=5|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=10|pillScore=2}}
+==References==
+{{reflist|2}}
-==Footnotes==
+[[Category:Drug]]
-<references/>
+[[Category:Cardiovascular Drugs]]
+[[Category:Antihypertensive agents]]
+[[Category:Diuretics]]
-{{Antihypertensives and diuretics}}
 [[Category:Thiazides]]
-[[Category:Drugs]]
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}

Clinical data


Pregnancy category	Risk neonatal thrombocytopenia in 3rd trimester^[1]
Routes of administration	oral
ATC code	C03AA01 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	100%
Protein binding	96%
Metabolism	extensive
Elimination half-life	3-4 hours^[2]
Identifiers
IUPAC name 3-benzyl-5,5-dioxo-9- (trifluoromethyl)-5λ⁶- thia-2,4-diazabicyclo[4.4.0]deca-7, 9,11-triene-8-sulfonamide
CAS Number	73-48-3
PubChem CID	2315
DrugBank	APRD00666
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₅H₁₄F₃N₃O₄S₂
Molar mass	421.417 g/mol